Skip to main content

Acadia Pharmaceuticals Inc.

corporate_fare Company Profile

Acadia Pharmaceuticals Inc.

ACAD·NASDAQ·Life Sciences·CIK 0001070494

ACADIA PHARMACEUTICALS INC is a biopharmaceutical company focused on developing innovations for underserved neurological and rare disease communities globally. The company operates with two core franchises: neurological disease and rare disease. Its neurological disease franchise is centered on NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). The rare disease franchise is anchored by DAYBUE, the first and only drug approved for the treatment of Rett syndrome. Net product sales from NUPLAZID and DAYBUE combined were $1,071.5 million for 2025, an increase from $957.8 million for 2024. Beyond these commercial products, ACADIA PHARMACEUTICALS INC maintains a portfolio of product candidates and research programs aimed at significant unmet medical needs in neurological and rare diseases. The most advanced product candidate is remlifanserin (formerly ACP-204), which is being developed for Alzheimer's disease psychosis (ADP) and Lewy Body Dementia Psychosis (LBDP). A Phase 2 study evaluating remlifanserin for hallucinations and delusions associated with ADP was initiated in November 2023. An additional Phase 2 study of remlifanserin in LBDP began in September 2025. In the fourth quarter of 2025, the company initiated a Phase 2 study of ACP-211 for the treatment of major depressive disorder (MDD). Several other product candidates are in earlier stages of development for neurological and rare diseases.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ACAD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Acadia Pharmaceuticals Reports Strong Q4 & Full Year 2025 Results, Exceeds $1B Revenue, and Issues Positive 2026 Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.07B
Net Income
$391M
Diluted EPS
$2.30
Op. Cash Flow
$109.84M
Free Cash Flow
$105.15M
Gross Profit
$982.51M
Operating Income
$104.81M
Cash & Equivalents
$177.69M
Debt / Equity
0.00×
Net Margin
36.5%
Shares Outstanding
170.31M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-072519
$17.12 +0.06% today
52-week range · as of 2026-11-04 $17.12 – $30.96
Market cap
$2.96B
Volume
1.9M (0.8× avg)
3-mo avg 2.4M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACAD - Filings & News (Page 2)

ACAD
Feb 25, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $17.12 info
Change: -$8.88 (-34%) info
Market Cap: $2.957B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets